Research Summary

Zoe Quandt, MD MS, is an endocrinologist and physician scientist. Her research and clinical care is focused on understanding endocrine side effects of cancer care, particularly immune related adverse events from cancer immunotherapy. She leads the UCSF Metabolic and Endocrine Cancer Immunotherapy Toxicity (MEND-IT) Clinic.

Education

BA, - Biology, Brown University
Residency, - Internal Medicine, Stanford Hospital and Clinics
MS, - Health and Medical Sciences, UC Berkeley
Fellowship, - Endocrinology and Diabetes, UCSF
MD, - Medical School, UCSF

Selected Publications

  1. Samantha Stone, Zaki Wilmot, Zoe Quandt, Aik Choon Tan, Samantha Liang, Enjun Yang, John Connolly, Arabella Young Investigating the influence of baseline medications on immune checkpoint inhibitor treatment outcomes for cancer patients 3706.  View on PubMed
  2. Aye Khine, Alyson Haslam, Vinayak Prasad, Zoe Quandt MON-362 Endocrine Immune-Related Adverse Events in Immune Checkpoint Inhibitor Therapy: Insights Across Cancer Types and Treatment Stages.  View on PubMed
  3. Zoe Quandt, Shivaram Yellamilli, Emily Flynn, Vrinda Johri, Brittany Davidson, Jessica Tsui, Alexis Combes, Gabriela Fragiadakis, Arabella Young, Mark Anderson SUN-565 High-dimensional Immunophenotyping of Immune Checkpoint Inhibitor-Induced Type 1 Diabetes.  View on PubMed
  4. Zoe Quandt Abstract IA05: Endocrine organs in the crosshairs of the immune system.  View on PubMed
  5. Quandt Z, Young A, Barlow GL, Smith JA, Kusmartseva I, Dong S, Shapiro MR, Kang JH, Felton JL, Nguyen VQ, Szot G, Hassoun AA, Perdigoto AL, Herold KC, Nolan G, Bollyky PL, Brusko TM, Nakayama M, Cooper S, Anderson MS Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas.  View on PubMed
  6. Liang SI, Quandt Z, Wienke S, Wang J, Gordon S, Barnett RM, Masannat J, Chang K, Espenschied CR, Quinn KJ, Banks KC, Yang E, Connolly JE Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study.  View on PubMed
  7. Huang NL, Ortega JG, Kimbrell K, Lee J, Scott LN, Peluso EM, Wang SJ, Kao EY, Kim K, Olay J, Nguyen JN, Quandt Z, Angell TE, Su MA, Lechner MG Polyfunctional T follicular helper cells drive checkpoint-inhibitor diabetes and are targeted by JAK inhibitor therapy.  View on PubMed
  8. Khine A, Quandt Z From Prediction to Prevention: The Intricacies of Islet Autoantibodies in Type 1 Diabetes.  View on PubMed
  9. AYE H. KHINE, RYAN PARK, STEPHEN E. GITELMAN, ZOE QUANDT. 1516-P: EMR-Based Insights Into T1D Screening Patient Volume. Diabetes. 2025 Jun 20; 74(Supplement_1).  View on PubMed
  10. Saya Jacob, Samantha Fisch, Carolyne Face, Kelly Blum, Madhuri Chengappa, Saliha Chaudhry, Alexis LeVee, Nikita V. Baclig, Andrew Soliman, Laura Huppert, Zoe Quandt, Laura Quintal, Dame Idossa, Michelle Melisko, A. Jo Chien, Mi-Ok Kim, Joanne Mortimer, Kelly McCann, Anne Blaes, Hope S. Rugo. Abstract PS5-05: Late-onset immune toxicity incidence & risk factors in breast cancer: a multi-institutional study. Clinical Cancer Research. 2025 Jun 13; 31(12_Supplement):ps5-05-ps5-05.  View on PubMed
  11. Mader JK, Wong JC, Freckmann G, Garcia-Tirado J, Hirsch IB, Johnson SB, Kerr D, Kim SH, Lal R, Montaser E, O'Donnell H, Pleus S, Shah VN, Ayers AT, Ho CN, Biester T, Dovc K, Farrokhi F, Fleming A, Gillard P, Heinemann L, López-Díez R, Maahs DM, Mathieu C, Quandt Z, Rami-Merhar B, Wolf W, Klonoff DC. The Use of Continuous Glucose Monitoring to Diagnose Stage 2 Type 1 Diabetes. J Diabetes Sci Technol. 2025 May 30; 19322968251333441.  View on PubMed
  12. Quandt Z, Lucas A, Liang SI, Yang E, Stone S, Fadlullah MZH, Bayless NL, Marr SS, Thompson MA, Padron LJ, Bucktrout S, Butterfield LH, Tan AC, Herold KC, Bluestone JA, Anderson MS, Spencer CN, Young A, Connolly JE. Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study. J Immunother Cancer. 2025 May 12; 13(5).  View on PubMed
  13. Pooja Middha, Zoe Quandt, Karmugi Balaratnam, Eduardo Cardenas, Christina J. Falcon, Princess Margaret Lung Group, Matthew A. Gubens, Scott Huntsman, Khaleeq Khan, Min Li, Christine M. Lovly, Devalben Patel, Luna Jia Zhan, Melinda C. Aldrich, Geoffrey Liu, Adam J. Schoenfeld, Elad Ziv. Abstract 2276: Whole exome sequencing of immune-mediated colitis in cancer patients treated with immune checkpoint inhibitors. Cancer Research. 2025 Apr 21; 85(8_Supplement_1):2276-2276.  View on PubMed
  14. Quandt Z, Perdigoto A, Anderson MS, Herold KC. Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease. Cold Spring Harb Perspect Med. 2025 Apr 01; 15(4).  View on PubMed
  15. Middha P, Thummalapalli R, Quandt Z, Balaratnam K, Cardenas E, Falcon CJ, Margaret Lung Group P, Gubens MA, Huntsman S, Khan K, Li M, Lovly CM, Patel D, Zhan LJ, Liu G, Aldrich MC, Schoenfeld A, Ziv E. Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events. J Immunother Cancer. 2025 Mar 28; 13(3).  View on PubMed
  16. Bejan CA, Wang M, Venkateswaran S, Bergmann EA, Hiles L, Xu Y, Chandler GS, Brondfield S, Silverstein J, Wright F, de Dios K, Kim D, Mukherjee E, Krantz MS, Yao L, Johnson DB, Phillips EJ, Balko JM, Mohindra R, Quandt Z. irAE-GPT: Leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets. medRxiv. 2025 Mar 06.  View on PubMed
  17. Huang N, Ortega J, Kimbrell K, Lee J, Scott LN, Peluso EM, Wang SJ, Kao E, Kim K, Olay J, Quandt Z, Angell TE, Su MA, Lechner MG. Polyfunctional IL-21+ IFNG+ T follicular helper cells contribute to checkpoint inhibitor diabetes mellitus and can be targeted by JAK inhibitor therapy. bioRxiv. 2024 Dec 03.  View on PubMed
  18. C.W. Thorball, Z. Quandt, A. Saha, L. Yao, P. Midda, Y. Xu, C.A. Bejan, F. Hodel, A. Stravodimou, E. Shearer-Kang, M. Aldrich, E.J. Philips, G. Liu, A. Schoenfeld, D. Johnson, E. Ziv, J. Fellay, R. Mohindra, J.M. Balko, G.S. Chandler. 67O Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity. Annals of Oncology. 2024 Sep 1; 35:s240-s241.  View on PubMed
  19. Quandt Z, Jacob S, Fadlullah MZH, Wu C, Wu C, Huppert L, Levine LS, Sison P, Tsai KK, Chow M, Kang JH, Hwang J, Lee JC, Oglesby A, Venegas J, Brintz BJ, Tan AC, Anderson MS, Rosenblum MD, Young A, Daud AI. Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response. BJC Rep. 2024 Jun 24; 2(1):46.  View on PubMed
  20. Middha P, Thummalapalli R, Quandt Z, Balaratnam K, Cardenas E, Falcon CJ, Princess Margaret Lung Group, Gubens MA, Huntsman S, Khan K, Li M, Lovly CM, Patel D, Zhan LJ, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E. Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events. medRxiv. 2024 Jun 11.  View on PubMed

Go to UCSF Profiles, powered by CTSI